Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

K Clément, Erica Akker, J Argente, A Bahm, Kuan Chung, H Connors

Research output: Contribution to journalArticleAcademicpeer-review

223 Citations (Scopus)
Original languageEnglish
Pages (from-to)960-970
Number of pages11
JournalThe Lancet Diabetes and Endocrinology
Volume8
Issue number12
DOIs
Publication statusPublished - 2020

Research programs

  • EMC MM-01-54-01

Cite this